Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Pharmaceutical Executive Europe  E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecdigi
 
Survey
We asked 40 pharma leaders, how important is it for your company to have a social media 'tsar'?

Very important 50%
Somewhat important 38%
Not sure 12%
Not important 0%

Talk to us:
editor@pharmexeceurope.com

Advertise with us: jgray@advanstar.com


3 April, 2012
In this Issue
Fighting the Pain in Spain (and Beyond)
Spain's Esteve is embarking on an ambitious programme of expansion and innovation. But can it rise above the country's stifling economic gloom? More...
Guido Rasi's Race for EMA Respectability
The race is on! Can the European Medicines Agency prove it is deserving of trust before the European Parliament exposes it to the shame of refusing to approve its accounts? The deadlines are very tight. The final decision on the agency’s reputation will be taken by the Parliament in early May. More...
Should Smokers Cough Up for Cancer Research?
This June in the US, Californians will be asked whether smokers should subsidize research to treat diseases related to cigarettes. Ben Comer reports. More...
Does Your Portfolio Review Reflect What the Patient Really Wants?
The quest for 'radical' R&D innovation is often pursued at the expense of treatments with hidden blockbuster potential, writes Bert Spilker. More...
Also in this issue…
Europe's First Meeting for Clinical and Commercial Pharma: Zurich, May 7th
Medical Device Industry Under Siege? (Part 2)
10 Questions to Ask When Evaluating eClinical Solutions